<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453464</url>
  </required_header>
  <id_info>
    <org_study_id>SIM129-mCRC-01</org_study_id>
    <nct_id>NCT02453464</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose-escalation study designed to assess the safety,&#xD;
      tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab)&#xD;
      Injection in combination with FOLFIRI in patients with previously treated metastatic&#xD;
      colorectal cancer. This study includes two stages. Stage 1 is the dose-escalation stage. Once&#xD;
      the maximum tolerated dose (MTD) of Sevacizumab has been established, additional patients&#xD;
      will be enrolled in the cohort-expansion stage (Stage 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>up to 56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (NCI-CTC 4.0)</measure>
    <time_frame>28 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters for Sevacizumab</measure>
    <time_frame>Cycle 1(Day3, Day4, Day7, Day10, Day13); Cycle 2-4(Day1);Cycle 4(Day1, Day2, Day5, Day8 ,Day11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters (Cmax, Tmax, AUC, T1/2) for Irinotecan and its major metabolite SN-38</measure>
    <time_frame>Day1, Day2, Day3, Day15, Day16, Day17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters for 5-FU</measure>
    <time_frame>Day1, Day3, Day15, Day17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biomarkers, including VEGF and ADA</measure>
    <time_frame>VEGF:Cycle 1(Day3, Day4, Day7, Day10, Day13); Cycle 2-4(Day1);Cycle 4(Day1, Day2, Day5, Day8, Day11); ADA : within 15 minutes before each Sevacizumab administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 3 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 3 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 3 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 3 years from date of registration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Sevacizumab+FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevacizumab</intervention_name>
    <description>escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg</description>
    <arm_group_label>Sevacizumab+FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity</description>
    <arm_group_label>Sevacizumab+FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity</description>
    <arm_group_label>Sevacizumab+FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity</description>
    <arm_group_label>Sevacizumab+FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological/cytological confirmed unresectable metastatic colorectal cancer patients&#xD;
             who have failed first-line oxaliplatin-based chemotherapy&#xD;
&#xD;
          -  At least one measurable lesion (according to RECIST 1.1 )&#xD;
&#xD;
          -  At least 4 weeks from the last chemotherapy. If patients received anti-tumor&#xD;
             biological products, at least four t1/2 of washout period is needed&#xD;
&#xD;
          -  Toxicity from previous treatment has to restore to ≤ grade 1 (NCI CTC4.0)&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate hematologic function: ANC ≥ 1.5 × 10^9 /L, HB ≥ 90 g /L (blood transfusion&#xD;
             allowed), PLT ≥ 100 ×10^9 /L; Adequate hepatic function: ALT ≤ 2.5 × ULN, AST ≤ 2.5 ×&#xD;
             ULN, TBIL ≤ 1.5 × ULN (patients with liver metastases ALT ≤ 5 × ULN, AST ≤ 5 × ULN);&#xD;
             Adequate renal function: creatinine ≤ 1 × ULN; Coagulation function: INR ≤ 1.5 × ULN,&#xD;
             APTT ≤ 1.5 × ULN&#xD;
&#xD;
          -  Patients of childbearing potential (male and female) must agree to use reliable&#xD;
             methods of contraception until at least 12 weeks after the last dose&#xD;
&#xD;
          -  Patients signed written inform consent&#xD;
&#xD;
          -  Willingness and capability to communicate with investigators and to comply with&#xD;
             protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HCV, TP or HIV antibody positive&#xD;
&#xD;
          -  Previously received anti-VEGF protein drugs, such as Bevacizumab,Sevacizumab&#xD;
&#xD;
          -  Previously treated with irinotecan&#xD;
&#xD;
          -  History of dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Patients with alcohol or drug dependence&#xD;
&#xD;
          -  Participation in other clinical trials within 4 weeks before enrollment&#xD;
&#xD;
          -  Active or chronic hepatitis B infection with HBV DNA &gt; 1.0 * 10^3 IU/mL&#xD;
&#xD;
          -  Serious infection requiring intravenous antibiotic therapy&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
&#xD;
          -  Patients with proteinuria at screening (urine protein ≥ 1+)&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, abdominal abscess within 6&#xD;
             months prior to enrollment&#xD;
&#xD;
          -  History of intestinal obstruction, inflammatory bowel disease, or other intestinal&#xD;
             diseases with chronic diarrhea as the major symptom&#xD;
&#xD;
          -  Serious non-healing wounds, ulcers or fractures&#xD;
&#xD;
          -  Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Active bleeding within 3 months prior to enrollment&#xD;
&#xD;
          -  Bleeding diathesis or coagulation disorder&#xD;
&#xD;
          -  History of arterial or venous thrombosis&#xD;
&#xD;
          -  History of myocardial infarction or stroke within 6 months prior to enrollment&#xD;
&#xD;
          -  Unstable angina, congestive heart failure, New York Heart Association (NYHA) class II&#xD;
             heart failure, uncontrollable arrhythmia, uncontrolled hypertension&#xD;
&#xD;
          -  Expected to receive surgery during the study or within 1 month after the last dose&#xD;
&#xD;
          -  The investigators consider the patients are not suitable for this trial&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Known allergies to any excipient in the study drug&#xD;
&#xD;
          -  Patients can not complete this study for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haijun Li, MS</last_name>
    <phone>86-025-85560000</phone>
    <phone_ext>1625</phone_ext>
    <email>lihaijun@simcere.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhua Ding</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Xu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

